DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink Et Al US 20120022039A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink et al. (43) Pub. Date: Jan. 26, 2012 (54) NOVEL SUBSTITUTED INDANES, METHOD Publication Classification FOR THE PRODUCTION THEREOF, AND USE (51) Int. Cl. THEREOF AS DRUGS A 6LX 3L/397 (2006.01) C07D 207/06 (2006.01) C07D 2L/22 (2006.01) C07D 22.3/04 (2006.01) (75) Inventors: Lothar Schwink, Frankfurt am C07D 22L/22 (2006.01) Main (DE); Siegfried Stengelin, C07C 235/54 (2006.01) Frankfurt am Main (DE); Matthias C07D 307/14 (2006.01) Gossel, Frankfurt am Main (DE); A63L/35 (2006.01) Klaus Wirth, Frankfurt am Main A6II 3/40 (2006.01) (DE) A6II 3/445 (2006.01) A6II 3/55 (2006.01) A63L/439 (2006.01) A6II 3/66 (2006.01) (73) Assignee: SANOFI, Paris (FR) A6II 3/34 (2006.01) A6IP3/10 (2006.01) A6IP3/04 (2006.01) A6IP3/06 (2006.01) (21) Appl. No.: 13/201410 A6IPL/I6 (2006.01) A6IP3/00 (2006.01) C07D 309/04 (2006.01) (52) U.S. Cl. .................... 514/210.01; 549/426: 548/578; (22) PCT Filed: Feb. 12, 2010 546/205; 540/484; 546/112:564/176; 549/494; 514/459:514/408: 514/319; 514/212.01; 514/299; 514/622:514/471 (86). PCT No.: PCT/EP2010/051796 (57) ABSTRACT The invention relates to substituted indanes and derivatives S371 (c)(1), thereof, to physiologically acceptable salts and physiologi (2), (4) Date: Oct. 4, 2011 cally functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according (30) Foreign Application Priority Data to the invention or derivative thereof, and to the use of the Substituted indanes according to the invention and to deriva Feb. 13, 2009 (EP) .................................. O929O109.9 tives thereofas MCH antagonists. US 2012/0022039 A1 Jan. 26, 2012 NOVEL SUBSTITUTED INDANES, METHOD include 0 to 3 additional heteroatoms selected from the FOR THE PRODUCTION THEREOF, AND USE group of oxygen, nitrogen and Sulfur, where the heterocy THEREOF AS DRUGS clic ring system may additionally be substituted by F, Cl, Br, CF, CN, (C-C)-alkyl, (C-C)-cycloalkyl, O—(C- Cs)-alkyl, (C-C)-alkoxy-(C-C)-alkyl, hydroxy-(C- 0001. The invention relates to substituted indanes and C)-alkyl, oxo, CO(R18), CONOR 19)(R20), hydroxyl, derivatives thereof, and the physiologically compatible salts COO(R21), N(R22)CO(C-C)-alkyl, N(R23)(R24) or and physiologically functional derivatives thereof, to the SO(C-C)-alkyl: preparation thereof, to medicaments comprising at least one O011 R10, R11 substituted indane or derivative thereof, and to the use of the 0012 are each independently H, (C-C)-alkyl, inventive substituted indanes and derivatives thereofas medi hydroxy-(C-C)-alkyl, F, OH: Caments. 0002 Compounds which have a different pharmacologi 0013 R9, R13, R14, R16, R17, R18, R19, R20, R21, R22, cal action but whose overall structure is similar to that of the R23, R24, substituted indanes and derivatives thereof described in the 0.014) are each independently H, (C-C)-alkyl: present application have already been described in the prior O art, for example stimulants of endothelial NO synthase for 0.015 R16 and R17, R23 and R24 treatment of cardiovascular disorders in WO2002/064565, 0016 optionally form, together with the nitrogen atom antagonists of the dopamine D2 receptor or of the serotonin to which they are bonded, a 5-6-membered ring which, 2A (5HT2A) receptor for treatment of schizophrenia in apart from the nitrogen atom, may also include 0-1 fur WO2005056540, and PPAR agonists in WO2007039174. ther heteroatom from the group of NH, N—(C-C)- 0003. Further compounds with MCH-antagonistic action alkyl, oxygen and Sulfur, for treatment of obesity are described in the prior art (ex 0017 q, r are each independently 0, 1, 2, 3, 4, 5, 6; amples: WO2005047293, WO2004.092181, 0018. R12, R15 WO2005103039, WO2004024702, WO2001021577, 0.019 are each independently H, OH. F. O—(C-C)- WO2003035624, WO2002089729, WO2002006245, alkyl, S (C-C)-alkyl, CN, COO(R25), N(R26)CO WO2002002744. WO2002057233, WO2003045313, (C-C)-alkyl, N(R27)(R28), CONCR29)(R30), SO WO2003097047, WO20020101.46, WO 2003087044, (C-C)-alkyl, a 3-12-membered mono-, bi- or WO2003/087046, WO2001/021577, WO2007018248, spirocyclic ring which may contain one to four heteroa WO2008022979, US2008058423, WO2008/002575, toms from the group of N, O and S and the 3-12-mem WO2008/001160, WO2006/044293, WO2005/033063, bered ring may contain further Substituents such as F, Cl, US2005/0075324, US 2006/0247239). Reviews are given in Br, OH, CF, NO, CN, OCF, oxo, O (C-C)-alkyl, Rokosz, L.L., Expert Opin. Drug Discov, 2007, 2, 1301-1327 (C-C)-alkoxy-(C-C)-alkyl, S (C-C)-alkyl, (C- and Curr. Med. Chem. 2008, 15, 1025-1043. 0004. It was an object of the invention to provide novel C)-alkyl, (C-C)-alkenyl, (C-C)-cycloalkyl, compounds which bring about a reduction in weight in mam O—(C-C)-cycloalkyl, (C-C)-cycloalkenyl, mals and which are suitable for prevention of obesity and O—(C-C)-cycloalkenyl, (C-C)-alkynyl, N(R31) diabetes, and the various sequelae thereof. (R32), COO(R33), SO(C-C)-alkyl and COOH: 0005. A series of compounds which modulate the activity 0020 R25, R26, R27, R28, R29, R30, R31, R32, R33 of MCH receptors has been found. More particularly, the 0021 are each independently H, (C-C)-alkyl: compounds are notable for antagonism of MCH R1. The O invention therefore relates to compounds of the formula I 0022 R27 and R28, R29 and R30, R31 and R32 0023 each independently optionally form, together R3 R1 with the nitrogen atom to which they are bonded, a R7' M 5-6-membered ring which, apart from the nitrogenatom, R7 L1-N may also include 0-1 further heteroatom from the group O V of NH, N—(C-C)-alkyl, oxygen and sulfur, us R2 0024 L1 is C(R34)(R35), C(R36)(R37)C(R38)(R39), B-L2-A R4 (C-C)-cycloalkyl: 0.025 R2 may optionally be joined to one of the R34, R35, R36, R37, R38 or R39 radicals so as to form an in which optionally (C1-C6)-alkyl-substituted 5-6-membered 0006 R1 r1ng, 0007 is H. (C-C)-alkyl, (C-C)-alkoxy-(C-C)- 0026 R34, R35, R36, R37, R38, R39 alkyl, (C-C)-alkenyl, (C-C)-alkynyl, CO(R9). 0027 are each independently H, (C-C)-alkyl, (C(R10)(R11))-R12, CO(C(R13)(R14)),-R15, CO-O 0028 R3, R4, R5 (C-C)-alkyl, CO(C(R13)(R14))-N(R16)(R17); 0029) are each independently H, F, Cl, Br, I, OH, CF, 0008 R2 NO, CN, OCF. O—(C-C)-alkyl, S (C-C)-alkyl, 0009 is H. (C-C)-alkyl, (C-C)-alkoxy-(C-C)- O—(C-C)-alkoxy-(C-C)-alkyl, (C-C)-alkyl, CON alkyl, (C-C)-alkenyl, (C-Cs)-alkynyl, CO(R9), (R40)(R41), CO(R42): (C(R10)(R11))-R12, CO(C(R13)(R14)), R15, CO-O 0030 R40, R41, R42 (C-C)-alkyl, CO(C(R13)(R14))-N(R16)(R17); 0031) are each independently H, (C-C)-alkyl: O O 0010 R1 and R2 form, together with the nitrogen atom to 0032 R40 and R41 which they are bonded, a 4- to 10-membered mono-, bi- or 0033 each independently optionally form, together spirocyclic ring which, apart from the nitrogenatom, may with the nitrogen atom to which they are bonded, a US 2012/0022039 A1 Jan. 26, 2012 5-6-membered ring which, apart from the nitrogenatom, rine, chlorine, bromine and iodine, preferably fluorine, chlo may also include 0-1 further heteroatom from the group rine and bromine, particularly preferably fluorine. of NH, N—(C-C)-alkyl, oxygen and sulfur, 0049. Examples of alkyl groups are: methyl, ethyl, propyl, 0034 R6, R6', R7, R7 butyl, pentyl, hexyl, heptyl and octyl. Included therein are 0035) are each independently H. F. (C-C)-alkyl, OH, both the n-isomers of these radicals and branched isomers O—(C-C)-alkyl: Such as isopropyl, isobutyl, isopentyl, sec-butyl, tert-butyl, 0036 R8 is H., (C-C)-alkyl: neopentyl, 3.3-dimethylbutyl, etc. Unless stated otherwise, 0037 A is a 5-6-membered aromatic ring which may the term alkyl additionally also includes alkyl radicals which include up to 2 heteroatoms selected from the group of are unsubstituted or optionally substituted by one or more nitrogen, oxygen and Sulfur, and may be substituted by one (e.g. 1, 2, 3 or 4) further radicals from the group consisting of (C-C)-alkoxy or halogen. Examples of alkyl groups substi or more of the substituents H, F, Cl, Br, I, OH, CF, NO, tuted by halogen are fluorinated alkyl groups such as CF, CN, OCF. O—(C-C)-alkyl, O (C-C)-alkoxy-(C- CHF CHF, 3-fluoroprop-1-yl, 2.2,1,1-tetrafluoroethyl. The C.)-alkyl, (C-C)-alkyl, N(R43)(R44), SO CH, CON additional Substituents may appear in any desired position of (R45)(R46), N(R47)CO(R48), CO(R49): the alkyl radical. Unless defined otherwise, the alkyl radicals 0038 optionally, C(O)NR8 may be joined to an ortho sub are preferably unsubstituted. stituent of A via a bridge comprising one or two elements 0050 Cycloalkyl means in the context of the present appli from the group of carbon and nitrogen so as to form, cation cycloalkyl and cycloalkylalkyl (alkyl which is in turn overall, a 9- to 10-membered bicyclic ring: substituted by cycloalkyl), where cycloalkyl has at least 3 0039 R43, R44, R45, R46, R47, R48, R49 carbonatoms.
Load more

Recommended publications
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Carboxylesterases: Pharmacological Inhibition Regulated Expression and Transcriptional Involvement of Nuclear Receptors and Other Transcription Factors
    CARBOXYLESTERASES: PHARMACOLOGICAL INHIBITION REGULATED EXPRESSION AND TRANSCRIPTIONAL INVOLVEMENT OF NUCLEAR RECEPTORS AND OTHER TRANSCRIPTION FACTORS Yuanjun Shen1, Zhanquan Shi2 and Bingfang Yan2,3 Division of Pharmaceutical Sciences James L. Winkle College of Pharmacy University of Cincinnati Cincinnati, OH 45229 USA. Address Correspondence to: Dr. Bingfang Yan Division of Pharmaceutical Sciences James L. Winkle College of Pharmacy University of Cincinnati Cincinnati, OH 45229 Phone: (513) 558-6297 Fax: (513) 558-3233 E-mail: [email protected] Running Title: Regulated expression and inhibited activity of carboxylesterases FOOTNOTES 1 Current address: Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh Department of Medicine, Pittsburgh, PA 15261, USA. 2 Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA 3 To whom correspondence should be addressed. 4 This work was supported by National Institutes of Health Grants R01GM61988 and R01EB018748. 5 Abbreviation used: CAR, Constitutive androstane receptor; CES1, carboxylesterase-1; DEC1, Differentiated embryo chondrocyte-1; 5-FU: Fluorouracil; GR, Glucocorticoid receptor; IL-6, Interlekin- 6; LPS, Lipopolysaccharides; Nrf2, Nuclear factor (erythroid-derived 2)-like 2; p53, Tumor protein p53; PXR, Pregnane X receptor Carboxylesterases (CESs, E.C.3.1.1.1) constitute a large class of enzymes that determine the therapeutic efficacy and toxicity of ester/amide drugs. Without exceptions, all mammalian species studied express multiple forms of carboxylesterases. Two human carboxylesterases, CES1 and CES2, are major contributors to hydrolytic biotransformation. Recent studies have identified therapeutic agents that potently inhibit carboxylesterases-based catalysis. Some of them are reversible whereas others irreversible. The adrenergic antagonist carvedilol, for example, reversibly inhibits CES2 but this carboxylesterase is irreversibly inhibited by orlistat, a popular anti-obesity medicine.
    [Show full text]
  • Department of Pharmacology
    “A STUDY TO EXPLORE THE WEIGHT REDUCING PROPERTY OF DOLICHOS BIFLORUS AND METFORMIN USING OBESE RAT MODEL - MECHANISTIC STUDY” DISSERTATION SUBMITTED FOR M.D. PHARMACOLOGY THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY DEPARTMENT OF PHARMACOLOGY PSG INSTITUTE OF MEDICAL SCIENCES AND RESEARCH PEELAMEDU, COIMBATORE – 641004 TAMILNADU, INDIA MAY 2019 PSG INSTITUTE OF MEDICAL SCIENCES & RESEARCH COIMBATORE CERTIFICATE This is to certify that this dissertation entitled “A study to explore the weight reducing property of Dolichos Biflorus and Metformin using obese rat model- mechanistic study” by Dr. P. Mary Mala, is a work done by her during the period of study in the Department of Pharmacology from June 2016 to May 2019, under the guidance of Dr.K.Bhuvaneswari, M.D.PGDBE, Professor & HOD, Department of Pharmacology, PSG IMS&R. Dr.K.Bhuvaneswari M.D.,PGDBE Professor & HOD Department of Pharmacology PSG Institute of Medical Sciences & Research Coimbatore-04 Dr.S.Ramalingam M.D. Dean PSG Institute of Medical Sciences & Research Coimbatore-04 DECLARATION BY THE CANDIDATE I hereby declare that this dissertation entitled, “A study to explore the weight reducing property of Dolichos Biflorus and Metformin using obese rat model- mechanistic study”, is a bonafide work done by me under the guidance and supervision of Dr.K.Bhuvaneswari, HOD & Professor, Department of Pharmacology, PSG Institute of Medical Sciences & Research. This study was conducted at the PSG Institute of Medical Sciences & Research, Coimbatore, under the aegis of The Tamilnadu Dr.MGR Medical University, Chennai, as part of the requirement for the award of M.D. Degree in Pharmacology. Dr.Mary Mala.P, III Year postgraduate, Department of Pharmacology, PSG Institute of Medical Sciences & Research Coimbatore-04 CERTIFICATE This is to certify that this dissertation work titled “A study to explore the weight reducing property of Dolichos biflorus and Metformin using obese rat model- mechanistic study”, of the candidate Dr.Mary Mala.P with registration Number 201616302 for the award of M.D.
    [Show full text]
  • Neuropeptide Y6 Receptors Are Critical Regulators of Energy Metabolism
    NEUROPEPTIDE Y6 RECEPTORS ARE CRITICAL REGULATORS OF ENERGY METABOLISM Ernie Yulyaningsih A thesis in fulfilment of the requirements for the degree of Doctor of Philosophy St Vincent’s Clinical School Faculty of Medicine February 2014 Table of Contents GENERAL INTRODUCTION ....................................................................... 2 Obesity .......................................................................................................... 3 Regulators of energy homeostasis................................................................ 3 Neuropeptide Y ............................................................................................ 4 The Y1 receptor ......................................................................................... 6 The Y2 receptor ......................................................................................... 9 The Y4 receptor ....................................................................................... 16 The Y5 receptor ....................................................................................... 21 The Y6 receptor ....................................................................................... 25 Hypothesis and overall aims of the study .................................................. 28 EXPERIMENTAL PROCEDURES ............................................................. 29 Generation and genotyping of the Y6-/--LacZ mouse ................................ 30 Animal experiments ..................................................................................
    [Show full text]
  • Cyproterone Acetate in the Management of Polycystic Ovary Syndrome
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Journal of Rawalpindi Medical College Journal of Rawalpindi Medical College (JRMC); 2018;22(3): 262-265 Original Article Comparison of Metformin and Ethinyl Estradiol- Cyproterone Acetate in the Management of Polycystic Ovary Syndrome Sadaf Ajaib, Maimoona Ali Department of Gyanecology and Obstetrics, Military Hospital, Rawalpindi Abstract predisposition. The rudimentary quandary is in the hypothalamic pituitary axis leading to incremented Background: To compare ethinyl estradiol- LH/FSH ratio1. The cumulation of anovulation and cyproterone acetate and metformin for polycystic hyperandrogenism denotes the classic form of PCOS ovarian syndrome in terms of mean hirsutism score which exhibits the adverse metabolic phenotype of the and waist hip ratio (WHR). syndrome. Clinical and biochemical features of these Methods: A total of 120 patients (60 patients in patients may vary well-according to race, ethnicity and each group) were included in the study. Group-A the diagnostic criteria used. 2 Hyper-androgenism received metformin 500mg and group-B was given may result in acne and hirsutism. Hirsutism afflicts 5- ethinyl estradiol 35 mg as treatment of polycystic 15% of females and is a paramount denouement of ovary disease (PCOD), mean hirsuitism and waist to background hyper-androgenemia. The manifestations hip ratio was measured at 6months. Hirsuitism was of polycystic ovary syndrome depends largely on measured according to Ferriman Gallway score. obesity, which exacerbates the reproductive and Circumferences were measured with an metabolic aberrations in women tormented by PCOs. anthropometric tape over light clothing. Waist girth Further studies conclude that obesity might promote was measured at the minimum circumference the phenotypic expression of PCOS in a population at between the iliac crest and the rib cage and hip girth risk of this disease.1,2 at the maximum width and their ratio was calculated Well known risk determinants for cardiovascular as baseline and after 6 months of treatment.
    [Show full text]
  • Leeds Thesis Template
    System Interactions in the Regulation of Appetite University of Leeds Fiona Louise Wright BSc (Hons) Submitted in accordance with the requirements of the degree of Doctor of Philosophy The University of Leeds Institute of Psychological Sciences September 2013 ii The candidate confirms that the work submitted is her own, except where work which has formed part of jointly-authored publications has been included. The contribution of the candidate and the other authors to this work has been explicitly indicated below. The candidate confirms that appropriate credit has been given within the thesis where reference has been made to the work of others. (see page xxii) This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement © 2013 The University of Leeds and Fiona Louise Wright iii Acknowledgements First and foremost, I would like to sincerely thank Professor John Rodgers, my PhD supervisor. I could never give enough thanks for his guidance and support over the last four years. He is a truly wonderful supervisor, and his professional knowledge and skill has been continually inspiring. A thank you, as well, to my secondary supervisor, Amanda Harrison, for her supervision and encouragement during John’s absence at the start of this journey. Lisa Broadhead also deserves a special thank you for her company and help in the laboratory during the experimental parts of the thesis. I’d also like to acknowledge Neil Lowley for his wonderful technical help down in the lab. To my funding body, my parents, I owe more thanks than can be put into words.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Instituto Superior De Ciências Da Saúde Egas Moniz
    INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ MESTRADO INTEGRADO EM CIÊNCIAS FARMACÊUTICAS REGULAÇÃO DO COMPORTAMENTO ALIMENTAR E NOVOS ALVOS TERAPÊUTICOS Trabalho submetido por Christelle Sophia Paulino Rodrigues para a obtenção do grau de Mestre em Ciências Farmacêuticas Trabalho orientado por Doutora Véronique Sena Outubro de 2013 Agradecimentos Agradecimentos Embora esta tese seja individual, não poderia deixar de usar este espaço para agradecer quem me apoiou durante esta fase e durante os cinco anos anteriores aquando a minha formação académica. As palavras não são suficientes para descrever o sentimento de agradecimento, mas o sentimento é real e profundo. Em primeiro lugar, gostaria de agradecer o Instituto Superior de Ciências da Saúde Egas Moniz que me forneceu o ensino adequado para me ajudar a cumprir os meus objetivos. À professora Véronique pela presença, pela orientação, pelo tempo de dedicou e pela ajuda que forneceu. Este trabalho não teria existido sem a professora. À Salete e ao Francisco que se disponibilizaram para me ajudar a corrigir a gramática e a ortografia. Ao meus amigos, familiares e colegas, que sempre acreditaram em mim. Ao meu irmão, por ser quem é. Aos meus pais pelo apoio moral, pela dedicação, pelo carinho e pelos sacrifícios que fizeram para eu chegar ao fim desta etapa. Dedico-lhes esta tese por isso, e por tudo o mais que fizeram por mim. A todos, obrigado. 3 Regulação do comportamento alimentar e novo alvos terapêuticos Resumo O comportamento alimentar depende da regulação do equilíbrio entre a ingestão de calorias e o gasto energético. Esta regulação ocorre a nível cerebral onde o hipotálamo exerce um papel fundamental.
    [Show full text]
  • Liver Disease ISSUE BRIEF on LIVER DISEASE
    Liver Disease ISSUE BRIEF ON LIVER DISEASE Introduction Briefings such as this one are prepared in response to petitions to add new conditions to the list of qualifying conditions for the Minnesota medical cannabis program. The intention of these briefings is to present to the Commissioner of Health, to members of the Medical Cannabis Review Panel, and to interested members of the public scientific studies of cannabis products as therapy for the petitioned condition. Brief information on the condition and its current treatment is provided to help give context to the studies. The primary focus is on clinical trials and observational studies, but for many conditions there are few of these. A selection of articles on pre-clinical studies (typically laboratory and animal model studies) will be included, especially if there are few clinical trials or observational studies. Though interpretation of surveys is usually difficult because it is unclear whether responders represent the population of interest and because of unknown validity of responses, when published in peer-reviewed journals surveys will be included for completeness. When found, published recommendations or opinions of national organizations medical organizations will be included. Searches for published clinical trials and observational studies are performed using the National Library of Medicine’s MEDLINE database using key words appropriate for the petitioned condition. Articles that appeared to be results of clinical trials, observational studies, or review articles of such studies, were accessed for examination. References in the articles were studied to identify additional articles that were not found on the initial search. This continued in an iterative fashion until no additional relevant articles were found.
    [Show full text]
  • Investigation of Orlistat As an Intervention for Obesity and Cardiovascular Risk Factors: a Systematic Review
    Investigation of Orlistat as an intervention for obesity and cardiovascular risk factors: A systematic review Item Type Thesis or dissertation Authors Wrigley, Daniel K. Publisher University of Chester Download date 01/10/2021 07:35:59 Link to Item http://hdl.handle.net/10034/125056 This work has been submitted to ChesterRep – the University of Chester’s online research repository http://chesterrep.openrepository.com Author(s): Daniel K Wrigley Title: Investigation of Orlistat as an intervention for obesity and cardiovascular risk factors: A systematic review Date: November 2010 Originally published as: University of Chester MSc dissertation Example citation: Wrigley, D. K. (2010). Investigation of Orlistat as an intervention for obesity and cardiovascular risk factors: A systematic review. (Unpublished master’s thesis). University of Chester, United Kingdom. Version of item: Submitted version Available at: http://hdl.handle.net/10034/125056 Investigation of Orlistat as an Intervention for Obesity and Cardiovascular Risk Factors: A Systematic Review Daniel. K. Wrigley Acknowledgements I would like to acknowledge and thank Dr. Stephen Fallows for the support and guidance on how to construct and finalise my research project. Without his support, assistance, and supervision, this review would have been extremely difficult to complete. I would also like to acknowledge Dr. John Buckley, Mike Morris, and the administration team in the CENS department at the University of Chester, for their support and patience throughout the entirety of my masters degree. I would like to express my utmost gratitude to my father, Alan Wrigley, my mother, Sandra Kesteven, and grand-parents, Sheila and Kenneth Flintham, for their moral and financial support, without which my continuation into further education and the completion of this review would not have been possible.
    [Show full text]